Literature DB >> 20086032

Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.

Ritu Rana1, Yuping Chen, Stephen S Ferguson, Grace E Kissling, Sailesh Surapureddi, Joyce A Goldstein.   

Abstract

CYP2C enzymes are expressed constitutively and comprise approximately 20% of the total cytochrome P450 in human liver. However, the factors influencing the transcriptional regulation of the CYP2C subfamily have only been addressed recently. In the present study, we used primary cultures of human hepatocytes to investigate the role of HNF4alpha in the pregnane X receptor (PXR)/rifampicin-mediated up-regulation of CYP2C8, CYP2C9, and CYP2C19 gene expression. We first identified new proximal cis-acting HNF4alpha sites in the proximal CYP2C8 promoter [at -181 base pairs (bp) from the translation start site] and the CYP2C9 promoter (at -211 bp). Both sites bound HNF4alpha in gel shift assays. Thus, these and recent studies identified a total of three HNF4alpha sites in the CYP2C9 promoter and two in the CYP2C8 promoter. Mutational studies showed that the HNF4alpha sites are needed for up-regulation of the CYP2C8 and CYP2C9 promoters by rifampicin. Furthermore, silencing of HNF4alpha abolished transactivation of the CYP2C8 and CYP2C9 promoters by rifampicin. Constitutive promoter activity was also decreased. Quantitative polymerase chain reaction analysis demonstrated that silencing HNF4alpha reduced the constitutive expression of CYP2C8 (53%), CYP2C9 (55%), and CYP2C19 (43%) mRNAs and significantly decreased the magnitude of the rifampicin-mediated induction of CYP2C8 (6.6- versus 2.7-fold), CYP2C9 (3- versus 1.5-fold), and CYP2C19 (1.8- versus 1.1-fold). These results provide clear evidence that HNF4alpha contributes to the constitutive expression of the human CYP2C genes and is also important for up-regulation by the PXR agonist rifampicin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086032      PMCID: PMC2845933          DOI: 10.1124/dmd.109.030387

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  38 in total

1.  Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.

Authors:  G P Hayhurst; Y H Lee; G Lambert; J M Ward; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting.

Authors:  R Jover; R Bort; M J Gómez-Lechón; J V Castell
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

3.  Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.

Authors:  M Niemi; J T Backman; M Neuvonen; P J Neuvonen; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2001-06       Impact factor: 6.875

4.  Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1.

Authors:  Celia P Martínez-Jiménez; José V Castell; M José Gómez-Lechón; Ramiro Jover
Journal:  Mol Pharmacol       Date:  2006-08-01       Impact factor: 4.436

5.  Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha.

Authors:  Xunshan Ding; Kristin Lichti; Insook Kim; Frank J Gonzalez; Jeff L Staudinger
Journal:  J Biol Chem       Date:  2006-07-05       Impact factor: 5.157

6.  Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor.

Authors:  Sabine Gerbal-Chaloin; Martine Daujat; Jean-Marc Pascussi; Lydiane Pichard-Garcia; Marie-Jose Vilarem; Patrick Maurel
Journal:  J Biol Chem       Date:  2001-10-25       Impact factor: 5.157

Review 7.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

8.  Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha.

Authors:  J Li; G Ning; S A Duncan
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

9.  Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA.

Authors:  Yoshiteru Kamiyama; Tsutomu Matsubara; Kouichi Yoshinari; Kiyoshi Nagata; Hidetaka Kamimura; Yasushi Yamazoe
Journal:  Drug Metab Pharmacokinet       Date:  2007-08       Impact factor: 3.614

10.  Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha.

Authors:  Sailesh Surapureddi; Ritu Rana; Janardan K Reddy; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2008-06-13       Impact factor: 4.436

View more
  16 in total

1.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

Review 2.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.

Authors:  Antonia H Tolson; Hongbing Wang
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

3.  CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: application to the development of a metabolically competent human hepatic cell model.

Authors:  Marta Benet; Agustín Lahoz; Carla Guzmán; José V Castell; Ramiro Jover
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

4.  CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver.

Authors:  Ngome L Makia; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2015-10-14       Impact factor: 4.436

5.  RBCK1, an E3 ubiquitin ligase, interacts with and ubiquinates the human pregnane X receptor.

Authors:  Ritu Rana; Sherry Coulter; Harriet Kinyamu; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2012-11-15       Impact factor: 3.922

6.  Med25 is required for RNA polymerase II recruitment to specific promoters, thus regulating xenobiotic and lipid metabolism in human liver.

Authors:  Ritu Rana; Sailesh Surapureddi; Waynekid Kam; Stephen Ferguson; Joyce A Goldstein
Journal:  Mol Cell Biol       Date:  2010-12-06       Impact factor: 4.272

7.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Authors:  Stuart A Scott; Katrin Sangkuhl; Alan R Shuldiner; Jean-Sébastien Hulot; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

Review 8.  Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

Authors:  Yakun Chen; Yong Tang; Changxiong Guo; Jiuhui Wang; Debasish Boral; Daotai Nie
Journal:  Biochem Pharmacol       Date:  2012-02-04       Impact factor: 5.858

9.  A Transcriptional Regulatory Network Containing Nuclear Receptors and Long Noncoding RNAs Controls Basal and Drug-Induced Expression of Cytochrome P450s in HepaRG Cells.

Authors:  Liming Chen; Yifan Bao; Stephanie C Piekos; Kexin Zhu; Lirong Zhang; Xiao-Bo Zhong
Journal:  Mol Pharmacol       Date:  2018-04-24       Impact factor: 4.436

10.  Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.

Authors:  Nuala Ann Helsby; Kathryn Elisa Burns
Journal:  Front Genet       Date:  2012-10-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.